What does a great biotech investment actually look like, and why do so many “platform” stories miss? Shelby Partner, Compound VC breaks down a playbook forged across therapeutics, diagnostics, and lab automation. We go deep on why mechanistic understanding predicts success, how diagnostics become data businesses, and why the next wave of value may come from closed loop automated labs hardware + software that finally links the whole bench. We explore faster paths to human evidence compassionate use, phase 0 trials, and cassette microdosing, and how biobanks move discovery closer to patients “start with humans because you end with humans”. Shelby also explains why RNA secondary structure targeting with covalent small molecules could merge phenotypic and target based discovery inside one company. And then we get wonderfully weird. We discuss manufacturing as value capture in a world where intelligence designs drugs, gene edited flowers as a low regulation high margin venture canvas, and what it means when biohackers and LLMs push healthcare outside traditional borders.